“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy

Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.